Immunai Stock

HealthTech

Looking to sell Immunai stock or options?

Founded: 2018Funding to Date: $295M

Immunai, a developer of immune system technology, is aimed at providing treatments for oncology and auto-immune disorders. The company's platform merges comprehensive mapping and reprogramming of the immune system with single-cell biology, AI, and machine learning. This provides novel insights into the immune system and enables healthcare researchers to speed up drug development and enhance patient outcomes.

Investors Include:

Meron Capital, Endless Frontier Labs, 8VC, Alexandria Venture Investments, Gefen Capital, Perot Jain, Dexcel Pharma, Piedmont Capital Investments, Talos Ventures, Duquesne Family Office, iAngels, TLV Partners, Schusterman Family Investments, ICON (Palo Alto), R-Squared Ventures, Koch Disruptive Technologies, Gad Allon, Piedmont, Viola Ventures, Catalio Capital Management.

Looking to sell Immunai Stock or Options?

We have an even better solution: The Collective Exchange Fund

Get in touch and see if we can help you